Mission Therapeutics has announced that MTX652, its Phase 2-ready USP30 inhibitor for acute kidney injury, has been acquired by Australian Stock Exchange-listed renal specialist Dimerix in a ...
CT angiography of the abdomen showed occlusion of the proximal left main renal artery with global hypoperfusion of the left kidney (arrow). A ...
Monsoon illnesses can affect more than your overall health. Know how dengue, UTIs and other seasonal infections may harm the ...
Mission Therapeutics has agreed to divest its phase 2‑ready acute kidney injury candidate MTX652 to Australian renal ...
Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditionsCompany is exploring development, licensing, and ...
A recent study published in the Journal of the American Medical Association revealed that acute kidney injury (AKI) in ...
Most Diabetic Patients With Atypical Renal Features Have Non-Diabetic Kidney Disease, Suggests Study
A recent retrospective study published in the Indian Journal of Nephrology in February 2026 reveals that 60.79% of diabetic ...
Highlights Dimerix acquires Phase 2-ready asset, DMX-652 - with potential for rapid advancement into a Phase 2 clinical study under an open US Investigational New ...
Mission Therapeutics of the UK has struck a deal to out-license a drug for acute kidney injury to Australia's Dimerix, ...
UK biotech company Mission Therapeutics has agreed to hand its acute kidney injury candidate MTX652 to Australian renal ...
Five women in Rajasthan seeking help after alleged postpartum kidney failure have drawn attention to postpartum acute kidney ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results